You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient, cancer, and treatment characteristics, by duration of filgrastim prophylaxis

From: Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis

  Study population, by days of filgrastim prophylaxis
  1-3 (n = 8,371) 4-6 (n = 3,691) > = 7 (n = 2,226)
Patient
Age (years), mean (SD) 54.1 (12.5) 57.4 (13.7) 59.2 (12.9)
Men, % 23.5 23.1 21.7
Chronic comorbidities, %
   Cardiovascular disease 1.6 2.0 1.9
   Diabetes 8.2 10.2 7.3
   Liver disease 1.0 0.9 0.5
   Renal disease 0.9 1.0 1.4
History of other Conditions/ Events Prior to Chemotherapy Course, %
   Anemia 15.2 12.3 14.5
   Neutropenia 6.1 5.5 5.7
   Other blood disorders 2.2 2.0 2.4
   Infection 24.6 33.1 35.8
   History of hospitalization for any reason, % 50.6 49.3 49.7
   History of CINC-related hospitalization, % 6.6 9.1 10.4
   History of chemotherapy, % 9.0 6.4 6.9
   History of radiation therapy, % 6.5 4.3 4.0
Pre-Chemotherapy Expenditures ($), Mean ± SD 34,736 (43,618) 33,913 (42,458) 34,480 (43,828)
History of conditions/ events in prior cycles of same chemotherapy course, %
   Anemia 18.5 18.5 19.6
   Neutropenia 38.0 45.4 44.9
   Other blood disorders 1.5 1.5 2.2
   Infection 31.9 34.2 34.3
Cancer    
Type, %    
   Female breast 48.2 49.6 49.6
   Non-Hodgkin’s Lymphoma 9.9 12.8 23.3
   Trachea, bronchus, lung 7.5 9.5 8.1
   Prostate 0.6 0.5 0.1
   Colon/Rectum 15.9 9.8 4.6
   Other 17.9 17.9 14.2
Presence of metastases, %
   Bone 2.5 1.5 1.8
   Other Site 35.1 30.3 29.6
Chemotherapy
Cycle number/ min. length of prior cycles in same chemotherapy course, %
  1 12.6 13.1 16.3
  2/12-19 5.9 4.3 4.8
  2/20-26 8.3 10.8 12.1
  2/27+ 2.1 3.0 2.7
  > = 3/12-19 41.5 31.8 21.1
  > = 3/20-26 27.8 35.3 40.5
  > = 3/27+ 1.7 1.8 2.5
Number of Myelosuppressive Drugs, %
  1 24.3 20.0 14.5
  2 48.0 48.2 51.3
  3 20.6 25.4 31.3
  > = 4 7.1 6.4 3.0
Receipt of Antimicrobial Prophylaxis, % 6.7 7.5 7.5
Year of Chemotherapy, %
  2001-2003 19.2 19.0 26.9
  2004-2006 39.2 34.2 34.2
  2007-2010 41.7 46.8 38.9